Ignite Creation Date:
2025-12-25 @ 3:52 AM
Ignite Modification Date:
2026-02-26 @ 12:36 AM
Study NCT ID:
NCT04323202
Status:
COMPLETED
Last Update Posted:
2025-10-24
First Post:
2020-03-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N
Sponsor:
Case Comprehensive Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-04
Start Date Type:
ACTUAL
Primary Completion Date:
2024-07-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-06-25
Completion Date Type:
ACTUAL
First Submit Date:
2020-03-20
First Submit QC Date:
None
Study First Post Date:
2020-03-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-23
Last Update Post Date:
2025-10-24
Last Update Post Date Type:
ESTIMATED